Antares Pharma Announces Additional U.S. Patent Protection for OTREXUP™
November 26 2013 - 7:00AM
Business Wire
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance
of U.S. Patent 8,579,865. This new patent is related to a
previously issued U.S. patent 8,480,631, and includes additional
claims that describe injection devices for the subcutaneous
delivery of methotrexate. The expiry date for this patent is 2030.
The issuance of this patent further protects the OTREXUP™ injection
system by describing the injector and methods of use resulting in
methotrexate blood levels bioequivalent to needle and syringe
injections. With the addition of this patent, there are now 7
patents listed in the Orange Book related to OTREXUP™.
“We continue to make significant progress in our efforts to
patent-protect our first in-house proprietary product OTREXUP™, as
well as the Medi-Jet device technology,” said Paul K. Wotton,
Ph.D., President and Chief Executive Officer. “We plan to pursue
additional patents on current and future proprietary programs in
order to derive maximum commercial value for our shareholders.
Intellectual property is one of our most important assets and we
will work aggressively toward growing our increasing portfolio of
patents while developing and commercializing our VIBEX® and
QuickShot™ products.”
About Antares Pharma
Antares Pharma focuses on self-administered parenteral
pharmaceutical products and topical gel-based medicines. The
Company has received marketing approval from the U.S. Food and Drug
Administration for OTREXUP™ (methotrexate) injection for the
treatment of adults with severe active rheumatoid arthritis,
children with active polyarticular juvenile idiopathic arthritis
and adults with severe recalcitrant psoriasis. Antares Pharma is
also developing VIBEX® QS T for testosterone replacement therapy.
The Company's technology platforms include VIBEX® disposable
Medi-Jet, disposable multi-use pen injectors and Vision™ reusable
needle-free injectors marketed as Tjet® and Zomajet® by Teva
Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals
(Ferring), respectively. Antares Pharma has a multi-product deal
with Teva that includes Tev-Tropin® [somatropin (rDNA origin) for
injection] human growth hormone (hGH), VIBEX® epinephrine and
several other products. Antares Pharma’s partnership with Ferring
includes Zomacton® hGH (somatropin) injection. In the U.S. Antares
has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a
treatment for overactive bladder that is marketed by Actavis.
Elestrin® (estradiol gel) is FDA approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause,
and is marketed in the U.S. by Meda Pharma. Antares Pharma has two
facilities in the U.S. The Parenteral Products Group located in
Minneapolis, Minnesota directs the manufacturing and marketing of
the Company’s reusable needle-free injection devices and related
disposables, and develops its disposable pressure-assisted Medi-Jet
and pen injector systems. The Company’s corporate office and
Product Development and Commercial Groups are located in Ewing, New
Jersey.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These statements are indicated by
the words “may,” “will,” “plans,” “intends,” “believes,” “expects,”
“anticipates,” “potential,” “could,” “would,” “should,” and similar
expressions, and includes statements regarding the ability of
additional patents on current and future proprietary programs
deriving maximum commercial value. Such forward-looking statements
are not guarantees of future performance and are subject to risks
and uncertainties that may cause actual results to differ
materially from those anticipated by the forward-looking
statements. These risks and uncertainties include, among others,
changes in revenue growth and difficulties or delays in the
commercial launch of OTREXUP™ for rheumatoid arthritis and
psoriasis, market acceptance by physicians and patients of new
products, delays in product development and changes or delays in
the regulatory process for existing or new product candidates.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2012, and in the Company's other periodic
reports and filings with the Securities and Exchange Commission.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Antares Pharma, Inc.Investor Contact:Jack HowarthVice
President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024